Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation

SIMPLE SUMMARY: Optimal cancer treatment requires the selection of patients based on the characteristics of their tumors. This review explores various strategies to select patients for DNA double strand break-inducing agents, such as PARP inhibitors. Patients with germline BRCA1/2 mutations benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladan, Marjolijn M., van Gent, Dik C., Jager, Agnes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957671/
https://www.ncbi.nlm.nih.gov/pubmed/33670893
http://dx.doi.org/10.3390/cancers13051004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957671/
https://www.ncbi.nlm.nih.gov/pubmed/33670893
http://dx.doi.org/10.3390/cancers13051004

Ejemplares similares